Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Roth

Showing results (201-210 of 225) with videos related to

Pageof 23
Sort By:
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Acta Neuropathologica|June 27, 2023
A T-cell antigen atlas for meningioma: novel options for immunotherapyGioele Medici, Lena K Freudenmann, Julia Velz, et al.
Oncotarget|November 24, 2016
Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Neuro-Oncology|March 19, 2024
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trialPatrick Roth, Thierry Gorlia, Jaap C Reijneveld, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Pageof 23

Showing results (201-210 of 225) with videos related to

Sort By:
Pageof 23
Blood|September 26, 2018
Hyper-<i>N</i>-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2016
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)Wolfgang Wick, Thierry Gorlia, Pierre Bady, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|February 28, 2025
Treatment persistence and clinical outcomes in patients starting B cell depleting therapies within the Swiss MS CohortGiulio Disanto, Sabine Schaedelin, Johanna Oechtering, et al.
Acta Neuropathologica|June 27, 2023
A T-cell antigen atlas for meningioma: novel options for immunotherapyGioele Medici, Lena K Freudenmann, Julia Velz, et al.
Oncotarget|November 24, 2016
Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Neuro-Oncology|March 19, 2024
Marizomib for patients with newly diagnosed glioblastoma: A randomized phase 3 trialPatrick Roth, Thierry Gorlia, Jaap C Reijneveld, et al.
Neurology. Clinical Practice|July 7, 2025
Treatment Strategies and Disease Activity During Pregnancy and Postpartum: Real-World Data From the Swiss Multiple Sclerosis CohortMaximilian Einsiedler, Chiara Zecca, Lisa Hofer, et al.
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
The Oncologist|January 22, 2026
Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysisOgechukwu A Asogwa, Linda Dirven, Neil K Aaronson, et al.
Pageof 23